Half-year review of the PREDILIFE liquidity contract as of June 30, 2024

Villejuif, France, July 19, 2024 - PREDILIFE, a company listed on Euronext Growth specializing in disease risk prediction for personalized medicine, presented the half-yearly report of its liquidity contract entrusted to TSAF - Tradition Securities And Futures.

As of June 30, 2024, the liquidity account included 3,028 PREDILIFE shares and €90,204.78, taking into account a return of 10,000 shares in December 2023. Compared to data from the end of 2023, this shows a slight decrease in the number of shares and an increase in available liquidity.

During the first half of 2024, the contract recorded the purchase of 9,749 shares and the sale of 9,961 shares, totaling €49,615.18 and €67,954.52 in capital respectively. Transactions for this period included 79 purchases and 67 sales.